According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Lisata Therapeutics Inc (hereinafter referred to as "Lisata Therapeutics") and its partner Kuva Labs have jointly decided to officially extend the deadline for the previously initiated equity acquisition offer to April 13, 2026.

This adjustment means that potential investors now have more time to assess and participate in the acquisition. The extension measure typically reflects the continued good faith of both parties in reaching a final agreement, while also providing the market with a more adequate response window. Industry observers have pointed out that such an extension of the offer period may be based on multiple factors, including current market conditions, investor feedback, or the need for further optimization of transaction details. As of the announcement, both parties have not disclosed any further specific changes to the terms.